The Argus Report
Photo for representational purpose only. | Photo Credit: AP The approval is for emergency use only in the treatment of cytokine release syndrome (CRS) in moderate to severe ARDS (acute respiratory distress syndrome) patients due to COVID-19 Biopharmaceuticals firm Biocon has received Drugs Controller General of India (DCGI) approval for use of its repurposed…
Read More »Biocon’s psoriasis drug gets DCGI nod for use in COVID-19 patients
